메뉴 건너뛰기




Volumn 106, Issue 4, 2003, Pages 626-631

Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine

Author keywords

Immunotherapy; Melanoma; Whole cell vaccine

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; BCG VACCINE; CANCER VACCINE; CARMUSTINE; CISPLATIN; DACARBAZINE; GAMMA INTERFERON; HETEROLOGOUS POLYVALENT MELANOMA WHOLE CELL VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; RECOMBINANT ALPHA2 INTERFERON; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINBLASTINE;

EID: 0042594373     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11242     Document Type: Article
Times cited : (21)

References (28)
  • 1
    • 0024490334 scopus 로고
    • Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma
    • Ahmann DL, Creagan ET, Hahn RG, Edmonson JH, Bisel HF, Schaid DJ. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989;63:224-7.
    • (1989) Cancer , vol.63 , pp. 224-227
    • Ahmann, D.L.1    Creagan, E.T.2    Hahn, R.G.3    Edmonson, J.H.4    Bisel, H.F.5    Schaid, D.J.6
  • 3
    • 0029086370 scopus 로고
    • Prognostic factors in 1,521 melanoma patients with distant metastasis
    • Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastasis. J Am Coll Surg 1995;181:193-201.
    • (1995) J Am Coll Surg , vol.181 , pp. 193-201
    • Barth, A.1    Wanek, L.A.2    Morton, D.L.3
  • 4
    • 0031805726 scopus 로고    scopus 로고
    • Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa and interleukin-2 for patients with metastatic melanoma
    • Bedikian A, Buzaid AC, Plager C, Papadopoulos N, Legha SA, Ring S, Eton O. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-9.
    • (1998) J Clin Oncol , vol.16 , pp. 1752-1759
    • Bedikian, A.1    Buzaid, A.C.2    Plager, C.3    Papadopoulos, N.4    Legha, S.A.5    Ring, S.6    Eton, O.7
  • 5
    • 0000709971 scopus 로고    scopus 로고
    • Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinbastine, temozolomide (CVT), interleukin-2 (IL-2) and interferon α-2b (IFN) in patients with metastatic melanoma
    • Atkins M, Gollob JA, Mier JW, McDermott DF, Tutin L, Sorokin P, Sosman JA. Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinbastine, temozolomide (CVT), interleukin-2 (IL-2) and interferon α-2b (IFN) in patients with metastatic melanoma. Proc ASCO 1998;17:507. Proc ASCO 2001. Abstract 1391.
    • (1998) Proc ASCO , vol.17 , pp. 507
    • Atkins, M.1    Gollob, J.A.2    Mier, J.W.3    McDermott, D.F.4    Tutin, L.5    Sorokin, P.6    Sosman, J.A.7
  • 6
    • 0042394339 scopus 로고    scopus 로고
    • Abstract 1391
    • Atkins M, Gollob JA, Mier JW, McDermott DF, Tutin L, Sorokin P, Sosman JA. Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinbastine, temozolomide (CVT), interleukin-2 (IL-2) and interferon α-2b (IFN) in patients with metastatic melanoma. Proc ASCO 1998;17:507. Proc ASCO 2001. Abstract 1391.
    • (2001) Proc ASCO
  • 9
    • 0033848628 scopus 로고    scopus 로고
    • High-dose aldesleukin therapy in patients with metastatic melanoma: Long-term survival update
    • Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose aldesleukin therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6:S11-S14.
    • (2000) Cancer J Sci Am , vol.6
    • Atkins, M.B.1    Kunkel, L.2    Sznol, M.3    Rosenberg, S.A.4
  • 11
    • 0026303386 scopus 로고
    • Attempts to optimize specific immunotherapy for melanoma
    • Mitchell MS: Attempts to optimize specific immunotherapy for melanoma. Int Rev Immunol 1991;7:331-47.
    • (1991) Int Rev Immunol , vol.7 , pp. 331-347
    • Mitchell, M.S.1
  • 13
    • 0031648808 scopus 로고    scopus 로고
    • Perspective on allogeneic melanoma lysates in active specific immunotherapy
    • Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;25:623-5.
    • (1998) Semin Oncol , vol.25 , pp. 623-625
    • Mitchell, M.S.1
  • 14
    • 0025147441 scopus 로고
    • Treatment of metastatic melanoma with an autologous tumor-cell vaccine. Clinical and immunologic results in 64 patients
    • Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine. Clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67.
    • (1990) J Clin Oncol , vol.8 , pp. 1858-1867
    • Berd, D.1    Maguire H.C., Jr.2    McCue, P.3    Mastrangelo, M.J.4
  • 17
    • 0033991158 scopus 로고    scopus 로고
    • Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance
    • Marincola FM, Jaffe EM, Hicklin DJ, Jaffee E, M.Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
    • (2000) Adv Immunol , vol.74 , pp. 181-273
    • Marincola, F.M.1    Jaffe, E.M.2    Hicklin, D.J.3    Jaffee, E.M.4    Hicklin, D.J.5    Ferrone, S.6
  • 18
    • 0035889708 scopus 로고    scopus 로고
    • Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: Regression of pulmonary metastasis
    • Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastasis. Int J Cancer 2001;94:531-9.
    • (2001) Int J Cancer , vol.94 , pp. 531-539
    • Berd, D.1    Sato, T.2    Cohn, H.3    Maguire H.C., Jr.4    Mastrangelo, M.J.5
  • 19
    • 0030057341 scopus 로고    scopus 로고
    • Vaccine therapy for malignant melanoma
    • Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46:225-44.
    • (1996) CA Cancer J Clin , vol.46 , pp. 225-244
    • Morton, D.L.1    Barth, A.2
  • 20
    • 0031713904 scopus 로고    scopus 로고
    • Correlation of specific immune responses with survival in melanoma patients with distant metastasis receiving polyvalent melanoma cell vaccine
    • Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastasis receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913-20.
    • (1998) J Clin Oncol , vol.16 , pp. 2913-2920
    • Hsueh, E.C.1    Gupta, R.K.2    Qi, K.3    Morton, D.L.4
  • 22
    • 0003708810 scopus 로고
    • Oxford: Oxford University Press
    • Leukocyte Typing IV, Knapp W. et al., eds. Oxford: Oxford University Press, 1989.
    • (1989) Leukocyte Typing IV
    • Knapp, W.1
  • 26
    • 0033557968 scopus 로고    scopus 로고
    • Tumor-induced interleukin-10 inhibits type I immune responses directed at a tumor antigen as well as a nontumor antigen present at the tumor site
    • Halak BK, Maguire Jr HC, Lattime EC. Tumor-induced interleukin-10 inhibits type I immune responses directed at a tumor antigen as well as a nontumor antigen present at the tumor site. Cancer Res 1999;59:911-7.
    • (1999) Cancer Res , vol.59 , pp. 911-917
    • Halak, B.K.1    Maguire H.C., Jr.2    Lattime, E.C.3
  • 27
    • 0033105695 scopus 로고    scopus 로고
    • Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells
    • Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J, Enk A. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood 1999;93:1634-42.
    • (1999) Blood , vol.93 , pp. 1634-1642
    • Steinbrink, K.1    Jonuleit, H.2    Müller, G.3    Schuler, G.4    Knop, J.5    Enk, A.6
  • 28
    • 0036134856 scopus 로고    scopus 로고
    • Cutting edge: IL-10-producing CD4+ T cells mediate tumor rejection
    • Segal BM, Glass DD, Shevach EM. Cutting edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 2002;168:1-4.
    • (2002) J Immunol , vol.168 , pp. 1-4
    • Segal, B.M.1    Glass, D.D.2    Shevach, E.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.